These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

788 related articles for article (PubMed ID: 31396935)

  • 1. An Improved Method to Produce Clinical-Scale Natural Killer Cells from Human Pluripotent Stem Cells.
    Zhu H; Kaufman DS
    Methods Mol Biol; 2019; 2048():107-119. PubMed ID: 31396935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy.
    Knorr DA; Ni Z; Hermanson D; Hexum MK; Bendzick L; Cooper LJ; Lee DA; Kaufman DS
    Stem Cells Transl Med; 2013 Apr; 2(4):274-83. PubMed ID: 23515118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural Killer Cells Generated From Human Induced Pluripotent Stem Cells Mature to CD56
    Euchner J; Sprissler J; Cathomen T; Fürst D; Schrezenmeier H; Debatin KM; Schwarz K; Felgentreff K
    Front Immunol; 2021; 12():640672. PubMed ID: 34017328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of "Off-the-Shelf" Natural Killer Cells from Peripheral Blood Cell-Derived Induced Pluripotent Stem Cells.
    Zeng J; Tang SY; Toh LL; Wang S
    Stem Cell Reports; 2017 Dec; 9(6):1796-1812. PubMed ID: 29173894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection and expansion of natural killer cells for NK cell-based immunotherapy.
    Becker PS; Suck G; Nowakowska P; Ullrich E; Seifried E; Bader P; Tonn T; Seidl C
    Cancer Immunol Immunother; 2016 Apr; 65(4):477-84. PubMed ID: 26810567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic and nature killer cell development from human pluripotent stem cells.
    Ni Z; Knorr DA; Kaufman DS
    Methods Mol Biol; 2013; 1029():33-41. PubMed ID: 23756940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy.
    Zhu H; Kaufman DS
    Blood Sci; 2019 Aug; 1(1):4-11. PubMed ID: 35402797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of natural killer cells from induced pluripotent stem cells under defined, serum- and feeder-free conditions.
    Lupo KB; Moon JI; Chambers AM; Matosevic S
    Cytotherapy; 2021 Oct; 23(10):939-952. PubMed ID: 34272175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of innate immune cells from human pluripotent stem cells.
    Bernareggi D; Pouyanfard S; Kaufman DS
    Exp Hematol; 2019 Mar; 71():13-23. PubMed ID: 30611869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer.
    Hermanson DL; Bendzick L; Pribyl L; McCullar V; Vogel RI; Miller JS; Geller MA; Kaufman DS
    Stem Cells; 2016 Jan; 34(1):93-101. PubMed ID: 26503833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy.
    Spanholtz J; Tordoir M; Eissens D; Preijers F; van der Meer A; Joosten I; Schaap N; de Witte TM; Dolstra H
    PLoS One; 2010 Feb; 5(2):e9221. PubMed ID: 20169160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro Differentiation of T Cells: From Human Embryonic Stem Cells and Induced Pluripotent Stem Cells.
    Iriguchi S; Kaneko S
    Methods Mol Biol; 2019; 2048():59-70. PubMed ID: 31396929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy.
    Iriguchi S; Yasui Y; Kawai Y; Arima S; Kunitomo M; Sato T; Ueda T; Minagawa A; Mishima Y; Yanagawa N; Baba Y; Miyake Y; Nakayama K; Takiguchi M; Shinohara T; Nakatsura T; Yasukawa M; Kassai Y; Hayashi A; Kaneko S
    Nat Commun; 2021 Jan; 12(1):430. PubMed ID: 33462228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Embryoid Bodies-Based Multilineage Differentiation of Human Embryonic Stem Cells Grown on Feeder-Free Conditions.
    Isaja L; Ferriol-Laffouillere SL; Mucci S; Rodríguez-Varela MS; Romorini L
    Methods Mol Biol; 2022; 2520():189-198. PubMed ID: 34611823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
    Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
    Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting.
    Goldenson BH; Hor P; Kaufman DS
    Front Immunol; 2022; 13():841107. PubMed ID: 35185932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability.
    Burridge PW; Thompson S; Millrod MA; Weinberg S; Yuan X; Peters A; Mahairaki V; Koliatsos VE; Tung L; Zambidis ET
    PLoS One; 2011 Apr; 6(4):e18293. PubMed ID: 21494607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rise of human stem cell-derived natural killer cells for cancer immunotherapy.
    Wang K; Han Y; Cho WC; Zhu H
    Expert Opin Biol Ther; 2019 Feb; 19(2):141-148. PubMed ID: 30583701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pluripotent stem cell-derived natural killer cells for cancer therapy.
    Knorr DA; Kaufman DS
    Transl Res; 2010 Sep; 156(3):147-54. PubMed ID: 20801411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient and simultaneous generation of hematopoietic and vascular progenitors from human induced pluripotent stem cells.
    Park TS; Zimmerlin L; Zambidis ET
    Cytometry A; 2013 Jan; 83(1):114-26. PubMed ID: 22736485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.